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Characterization of Contrast Agent Microbubbles
for Ultrasound Imaging and Therapy Research
Helen Mulvana, Richard J. Browning, Ying Luan, Nico de Jong,
Meng-Xing Tang, Robert J. Eckersley, and Eleanor Stride
Abstract— The high efficiency with which gas microbubbles
can scatter ultrasound compared with the surrounding blood pool
or tissues has led to their widespread employment as contrast
agents in ultrasound imaging. In recent years, their applications
have been extended to include super-resolution imaging and
the stimulation of localized bio-effects for therapy. The growing
exploitation of contrast agents in ultrasound and in particular
these recent developments have amplified the need to characterize
and fully understand microbubble behavior. The aim in doing
so is to more fully exploit their utility for both diagnostic
imaging and potential future therapeutic applications. This paper
presents the key characteristics of microbubbles that determine
their efficacy in diagnostic and therapeutic applications and the
corresponding techniques for their measurement. In each case,
we have presented information regarding the methods available
and their respective strengths and limitations, with the aim of
presenting information relevant to the selection of appropriate
characterization methods. First, we examine methods for deter-
mining the physical properties of microbubble suspensions and
then techniques for acoustic characterization of both suspensions
and single microbubbles. The next section covers characterization
of microbubbles as therapeutic agents, including as drug carriers
for which detailed understanding of their surface characteristics
and drug loading capacity is required. Finally, we discuss the
attempts that have been made to allow comparison across the
methods employed by various groups to characterize and describe
their microbubble suspensions and promote wider discussion and
comparison of microbubble behavior.
Index Terms— Acoustic microscopy and imaging, medical
imaging, therapeutics, ultrasound contrast agents (UCAs).
I. INTRODUCTION
GAS microbubbles are now in widespread use as contrastagents in ultrasound imaging as a result of their excep-
tional echogenicity [1], [2]. Over the past two decades, their
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ability to produce localized bio-effects for therapeutic applica-
tions particularly for the treatment of cancer [3], drug and gene
delivery [2], opening of the blood brain barrier [4], [5], and to
seed ablation of cancerous tissue during high-intensity focused
ultrasound [6] has also been widely investigated. In addition,
their use in super-resolution imaging techniques, which offer
unprecedented detail in ultrasound imaging, is currently being
explored [7], [8]. This rapid growth in exploitation has greatly
increased the need for better understanding of microbubble
behavior and hence for better characterization methods.
Ultrasound contrast agents (UCAs) are made up of gas
microbubbles, commonly a biologically inert fluorocarbon,
stabilized by a lipid, protein, or polymer shell. Several com-
mercial agents exist, and these are supplied either as a poly-
disperse suspension of preformed microbubbles or lyophilized
powder that is mixed with saline and agitated by the clinician
prior to use. The suspensions typically contain microbubbles
ranging in size from 1 to 10 µm in diameter corresponding
approximately to the size of a red blood cell (∼8 µm). This is
important if microbubbles are to remain within the vasculature
but able to traverse capillaries. It also mitigates the risk of
embolism presented by adding gas bubbles to the blood stream.
In addition, particularly for the purposes of research, contrast
agents can be fabricated in-house by means of sonication or
microfluidics, with the specific characteristics of the resulting
suspensions varying according to the fabrication technique and
materials employed.
The aim of this paper is to present the key characteristics
of microbubbles that determine their efficacy in diagnostic and
therapeutic applications and the corresponding techniques for
their measurement. In each case, we have presented infor-
mation regarding the methods available and their respective
strengths and limitations, with the aim of presenting informa-
tion relevant to the selection of appropriate characterization
methods. First, we examine methods for determining the phys-
ical properties of microbubble suspensions. Second, we exam-
ine techniques for acoustic characterization, both of microbub-
ble suspensions and single microbubbles. Third, we review
techniques appropriate to therapeutic applications, for which
detailed understanding of microbubble surface characteristics
and drug loading capacity is required. Finally, we discuss the
methods for comparing data sets from across the literature.
II. COUNTING AND SIZING
A. Introduction
The extent to which microbubbles are able to scatter
sound or generate bio-effects is a function of their oscillatory
This work is licensed under a Creative Commons Attribution 3.0 License. For more information, see http://creativecommons.org/licenses/by/3.0/
MULVANA et al.: CHARACTERIZATION OF CONTRAST AGENT MICROBUBBLES 233
Fig. 1. Undamped linear natural frequency of an air-filled microbubble as a
function of diameter calculated using Minnaert’s equation [214].
behavior when subject to the alternating pressure of an
ultrasound field. Upon exposure to ultrasound, the highly
compressible gas core of a microbubble causes it to undergo
a volumetric contraction and expansion. There is a fortunate
correlation between the range of microbubble sizes that is
appropriate for clinical use and that which is resonant, i.e.,
exhibits a maximum amplitude of expansion, at the range
of frequencies commonly employed in diagnostic ultrasound
imaging (1–15 MHz), as illustrated in Fig. 1. Thus, the dis-
tribution of sizes in a microbubble suspension is an important
factor both in predicting their individual fundamental response
[9] and in predicting the response of the population [10], [11].
Due to the range of microbubble preparations available and
their variability, it is essential that researchers can easily gener-
ate detailed size and concentration information for the partic-
ular suspension they intend to use. There are several methods
available for the sizing and counting of microbubbles, includ-
ing electro-impedance volumetric zone sensing, typically by
means of the commercial device known as a Coulter counter
or multisizer (Beckman Coulter Ltd., High Wycombe, U.K.),
laser diffraction (LD), commonly undertaken using a master-
sizer (Malvern Instruments, Worcestershire, U.K.), and optical
microscopy and single-particle optical light scattering. Each
method can deliver size distribution and/or concentration mea-
surements for suspensions of microbubbles and has particular
merits and limitations. For example, commercial devices offer
automation and provide swift analysis; however, the cost
of investing in and operating specialist equipment may be
limiting. In the case of LD, accuracy can be impaired by the
reliability of the scattering model used as a basis for sizing the
microbubbles due to variations in microbubble shape, the fluid
they are suspended in, and accuracy with which the refractive
index of the fluids involved can be estimated. Microscopy,
which is more time consuming than the alternatives, offers
excellent microbubble sizing accuracy. It also allows the
analysis to be easily customized to deliver information about
the size ranges of particular interest to ultrasound research. For
example, sizing metrics arising from LD can be skewed by the
high sensitivity of the technique to the sensing of nanoscale
to microscale bubbles. Since bubbles of these sizes do not
Fig. 2. Flowchart describing the main steps in optical microscopy for
microbubble sizing.
contribute significantly to the echogenicity of a microbubble
suspension at typical clinically applied frequencies [9], inclu-
sion in the analysis can result in a misleading set of suspension
metrics. A more detailed comparison and discussion of the
merits of electro-impedance, LD, and optical microscopy
can be found in [12]. This discussion has been extended
by Satinover et al. [13], who compared single-particle light
scattering sizing methods such as those employed in the
AccuSizer (Particle Sizing Systems, Santa Barbara, CA, USA)
with electrozone sensing. The authors use the generalized
Lorenz–Mie scattering theory to explain the resulting differ-
ences in measurement recorded, revealing that discrepancies in
sizing occur due to the nonlinearity of the relationship between
the extinction cross section of light scattering from a particle
and the diameter curve. They conclude that flow cytometry
can provide superior sizing information compared with light
obscuration methods because in the former, both the forward
and side scattering measurements are used for each particle to
calculate diameter.
B. Optical Microscopy for Microbubble
Suspension Characterization
Optical microscopy offers a readily accessible, low-cost, and
simple means of accurately sizing microbubble suspensions.
The main steps in sizing a suspension in this way are illustrated
in Fig. 2. The suspension is prepared, following either the
manufacturer’s instructions for commercial products or at
the concentration it will be used at for in-house fabricated
suspensions, and gently inverted to resuspend the bubbles.
A known volume of the suspension is added to 1 mL of saline,
and 10 µL of this diluted suspension is added to the counting
chamber of a hemocytometer using a 20-µL pipette (P20). The
hemocytometer is placed on a microscope stage and bub-
bles are allowed to rise under buoyancy to achieve a sta-
tic state. Using a 40× objective, the concentration of the
microbubble suspension is checked to confirm its suitability for
microscopy counting. The recommendation is that there are at
least 50 isolated microbubbles in the imaging frame. Should
this not be the case, then the dilution step should be repeated,
increasing or decreasing the volume of microbubble suspen-
sion added to the saline as appropriate. A series of individual
images sufficient to include at least 5000 individual microbub-
bles is acquired from the hemocytometer, as representative
of the suspension as a whole, and analyzed using MATLAB
(The Mathworks, Inc., Natick, MA, USA) to produce sizing
and concentration data as illustrated in Fig. 3. A detailed
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Fig. 3. Microbubble sizing using microscopy. (a) Typical bright field optical
microscope image of an albumin microbubble suspension. (b) Histogram
illustrating the size distribution as percentage number of the same suspension
obtained using the MATLAB-based statistical analysis program described
in [14].
explanation of this method of sizing microbubbles and infor-
mation regarding the image analysis used can be found in [14].
C. Optical Scattering Methods
LD is an alternative method for sizing and counting
microbubbles. In an LD analyzer (e.g., Mastersizer from
Malvern Instruments, Worcestershire, U.K.), diluted particles
are exposed to a laser beam and the angular light distribution
and intensity scattered from the particles are measured. Parti-
cles crossing the laser beam interact with the incident beam
through scattering and absorption to generate flux intensities
at angles inversely proportional to the size of the individual
particles. A theoretical model based on Mie or Fraunhofer
scattering theories can be used to determine the particle size
by fitting of the measured data. The Mie scattering model is
in general more accurate for small particles, particularly those
less than tens of micrometers down to tens of nanometers, but
requires knowledge of the refractive indices of the particles
and the medium. The refractive index of microbubbles can be
determined experimentally, e.g., on a polarizing microscope
using the Becke line method [15]. There are variations of the
Mie model, and for microbubbles, a model that does not ignore
particle absorption is recommended. Care should be taken to
use appropriate concentrations in order to minimize multiple
scattering at high particle densities. A study of the different
sizing and counting methods [12] has shown some relatively
large errors in the LD results compared with the optical
microscope or the electro-impedance volumetric zone sensing.
The errors are likely due to the inaccuracy in the estimation
of the complex refractive indices of the microbubbles.
D. Electro-Impedance Volumetric Zone Sensing
Electro-impedance volumetric zone sensing “Coulter” coun-
ters and similar instruments have been widely applied to
counting and sizing particles by measuring changes in the
electrical impedance of a sensing zone as individual parti-
cles pass through it. In a typical setup, test particles are
diluted in a conductive liquid, homogenized by stirring, and
pumped through the sensing zone across which electrodes are
placed. The count of changes in impedance measurements
corresponds to bubble count, while the amplitude of the
measurements, after calibration, corresponds to the size of the
particles. A recent study has shown that a Coulter counter can
generate highly reproducible results in sizing and counting
microbubbles [12].
A typical Coulter counter system requires differently sized
apertures to capture broad particle size distributions, as the
particle size range that can be determined using a given
aperture is of the order 2%–40% of the aperture [16], outside
of which errors could be significant. While coincident passage
of two or more particles through the sensing zone is a potential
source of error, this can be overcome by employing a pulse
discrimination system that rejects distorted pulses, which is
a common feature of modern commercial systems. However,
this could still potentially affect the counting results.
E. Important Points to Note
It is important to note that in order to produce data that
are relevant for in vivo microbubble applications, the potential
differences in environmental conditions capable of influenc-
ing microbubble stability, size, and concentration should be
carefully considered. It has been shown that both the tem-
perature and gas content of the suspending fluid can influence
microbubble stability and diameter [17]–[19]. It is also widely
accepted that microbubbles are particularly vulnerable to han-
dling and rapid changes in pressure that may be encountered
during transfer between solutions. Browning et al. [20] and
Barrack and Stride [21] showed that the shear stresses and
pressure gradients exerted by drawing suspensions through
a syringe and needle can lead to microbubble destruction.
In our labs, we have observed that microbubble stability can be
undermined for commercial contrast agents if the septum seal
is removed, exposing the suspension to the atmosphere rather
than the perfluorobutane or other gas included in the head
space of the vial. Each of these factors should be carefully
considered both in the preparation and handling of microbub-
ble suspensions and during examination and consideration of
the results.
The relatively recent development of phase change con-
trast agents has offered exciting opportunities for extending
the use of UCAs to the extravascular space [22]. Existing
micrometer-sized bubbles are purely blood pool agents as
they are too big to cross the endothelial wall (extravasation).
While this is an advantage for vascular imaging, they are
incapable of interrogating or delivering therapy within the
interstitial space, e.g., in solid tumors. Submicrometer bub-
bles are difficult to make and are not efficient in providing
image contrast. Phase change contrast agents are typically
perflurocarbon droplets that can be prepared with nanoscale
dimensions to facilitate their extravasation, after which they
can be vaporized to for microbubbles using ultrasound (or
other sources of energy). The characterization of such nan-
odroplets, however, is more challenging due to their size.
While a typical optical microscope can be used to visual-
ize some submicrometer droplets, it will not have sufficient
resolution to accurately size them. Dynamic Light Scattering
(DLS) is commonly used for sizing and counting such small
particles. Detailed characterization of their shape and surface
structure can also be achieved, for example, through the use
of transmission electron microscopy (TEM). The development
of higher frequency contrast imaging, requiring the use of
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Fig. 4. Schematics showing typical arrangements for measurement of
(a) acoustic attenuation and (b) acoustic scattering, where attenuation is calcu-
lated in decibels against a reference measurement taken with no microbubble
suspension in the propagation path and the received signal due to scattering
is calibrated against the known pressure response of the receive transducer to
derive scattered pressure in kilopascals.




Bulk acoustic measurements provide information about the
scattering and attenuation characteristics of a microbubble sus-
pension and are generally undertaken to provide information
that will allow acoustic performance in vivo to be anticipated.
A known quantity of microbubble suspension is added to a
vessel of water, itself positioned within a larger volume of
water for ease of acoustic coupling. The target vessel is posi-
tioned coincident with the focus of an ultrasound transducer
such that the sound can propagate through an acoustic window
and through the microbubble suspension within the vessel. The
suspension is gently agitated, typically using a magnetic stirrer,
to ensure that the interrogation volume is regularly replenished
with a fresh supply of suspended microbubbles in between
measurements. Acoustic signals are then collected using either
a matched transducer positioned at 90° from the excitation
source for acoustic scattering or a hydrophone positioned in
line with the excitation source for acoustic attenuation, and
acquired to a PC for postprocessing. Typical arrangements
used to perform such measurements are shown in Fig. 4, and
a more detailed explanation can be found in [23].
Comparable measurements can also be performed using a
clinical imaging system [24]. In each case, it is important
to ensure that the characteristics of the acoustic setup are
removed from the data and where a clinical imaging system
is used, that data can be accessed independent of proprietary
postprocessing, or alternatively that steps are made to mitigate
its effect, for example, by comparing data acquired under
identical conditions.
B. Methods of Standardizing Results for
Comparison Across Research Groups
Despite much attention having been given to the issues dis-
cussed above, ease of comparison of scattering and attenuation
data across research groups can be challenging. This is due in
part to the fact that no universally agreed system of comparison
exists and in part to the individual environmental and setup
conditions employed by different groups, as discussed in
Section I. In terms of comparison, a metric that combines
both scattering and attenuation measurements (linear and/or
nonlinear) has been proposed in the form of an index termed
the scattering to attenuation ratio (STAR) or nSTAR [25].
This index was established to describe the extent to which a
contrast agent can enhance the scattered acoustic signal from
a tissue perfused with contrast agent, while also presenting
information about the degree to which the agent contributes
to ultrasound absorption. However, the measure is equally
relevant to therapeutic ultrasound in which echogenicity and
treatment depth are of similar importance. Several groups have
used this approach to make comparisons across microbubble
formulations [26], [27]; however, it is not clear why it has not
been more widely adopted.
C. Single Microbubble Techniques
One drawback of bulk acoustic measurements is that they
do not provide any information regarding the variation in
acoustic response across a microbubble population. At a given
ultrasound frequency and pressure, both the amplitude and
nonlinear characteristics of the oscillation of an individual
microbubble are known to be highly dependent upon its size
and coating properties. In order to address this, several differ-
ent techniques have been developed using: 1) ultrahigh speed
video microscopy, which will be addressed in Section IV;
2) acoustic scattering measurements; and 3) laser scattering
measurements.
1) Acoustic Scattering:
a) Isolated capillary measurements: One of the simplest
methods of measuring individual microbubble responses is to
perform scattering measurements similar to those described
in Section III-A, but with a highly dilute suspension of
microbubbles, such that only a single bubble is present in the
focal volume of the transducer at any one time. In principle,
the same apparatus as described in Section III-A could be
used, but in practice, some means of aligning bubbles with
the transducer focus is desirable. One way to achieve this is
to confine the microbubbles within an acoustically transparent
tube whose diameter is large compared with the microbubble
but comparable or smaller than the acoustic wavelength. For
example, Casey et al. [28] utilized 200-µm diameter cellulose
dialysis tubing for this purpose. A highly dilute suspension
of microbubbles is drawn into the tube by capillary action
or under mild suction from a syringe pump. The capillary is
suspended in a water bath at the focus of a water immersion
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microscope objective lens. Suitable positions at which isolated
bubbles are located can then be identified. Ideally, the objective
and ultrasound transducer should be mounted on a position-
ing rig such that their foci coincide. Thus, once a suitable
microbubble has been identified, a scattering measurement can
be made.
There are a number of drawbacks to this technique, however.
First, it is relatively labor intensive and the rate at which
measurements can be made is quite low. This is undesirable as
it limits effective statistical analysis of microbubble population
characteristics. Second, confining the microbubbles in the cap-
illary will alter their response compared with that exhibited by
an unconfined microbubble [29]. Thus, the measured responses
will differ from those that might be expected in large blood
vessels or predicted by theoretical models. Third, it is difficult
to measure the sound field to which a microbubble will be
exposed with the microscope objective in situ. Thus, either
there will be some uncertainty in the exposure parameters
due to scattering from the objective or the objective must
be retracted immediately before the experiment at the risk of
agitating the fluid and causing the bubble to move.
b) Flow focusing: An alternative means of confining
microbubbles that avoids the need for a solid boundary is
to create a hydrodynamically focused stream of microbubbles
whose axis can be aligned with the transducer focal volume.
This is achieved using a pair of coaxially aligned nozzles
whose flow rates can be controlled individually, e.g., through
separate syringe pumps. The nozzles are immersed in the
liquid-filled chamber in which the scattering measurements are
to be made. The inner nozzle carries the bubble suspension and
the outer nozzle the so-called “sheath” flow that confines the
bubbles to a fine stream. By adding a small amount of dye
to the bubble suspension, the ultrasound transducer can be
optically aligned to this stream. Roos [30] and subsequently
Roy and Apfel [31] demonstrated the efficacy of this technique
for the acoustic characterization of red blood cells. It was
subsequently applied to microbubbles in [32] and [33].
It is still necessary to use a very dilute suspension of
microbubbles to minimize the risk of multiple bubbles passing
through the ultrasound focus simultaneously, but a signifi-
cantly higher rate of scattering measurements can be achieved
with this technique. The main drawback of this method is
the lack of feedback on microbubble position and hence
the precise pressure amplitude with which they are excited.
Acoustic pulses are transmitted at a set repetition frequency,
but there is no means of detecting where in the pressure
field, a microbubble is located when a scattering measurement
is recorded. Given the highly pressure-dependent nature of
microbubble scattering (unlike that of solid or liquid particles),
this introduces considerable uncertainty into the measure-
ments. In addition, it is not possible to determine the initial
size of each microbubble.
c) Acoustic “camera:” A more recent approach, pub-
lished in [34] utilizes a similar apparatus to that described
in Section III-A, but with three cofocally aligned ultra-
sound transducers. The first transducer is used to “drive”
the microbubbles in the range 1–10 MHz, while the second
and third transducers emit and receive pulses, respectively,
at a much higher frequency (30 MHz) in order to “image” the
microbubbles. The imaging frequency is sufficiently above the
microbubble resonance frequency for them to behave as linear
scatters, and thus the recorded pressure is directly proportional
to the bubble volume. The “camera” thus provides data that are
more directly comparable with those obtained with ultrahigh
speed imaging and can be more readily compared with theo-
retical predictions but with less stringent sampling frequency
restrictions. In its current form, the system suffers from the
same limitations as the flow focusing systems, namely, uncer-
tainty regarding initial bubble radius and acoustic excitation
pressure amplitude. Based on this acoustical measurement
setup, a combined optical sizing and acoustical characteriza-
tion technique was later developed [35]. A coaxial flow device
was used to direct individual microbubbles to the confocal
region of the ultrasound transducers and a high-resolution
microscope objective. Bright field images of microbubbles
flowing through the optical field of view were captured by
a high-speed imaging camera synchronous with the acoustical
recordings.
2) Optical Scattering: An alternative means of measuring
microbubble volume is to exploit the fact that an oscillating
microbubble will scatter light as well as sound. The principle is
similar to that of the acoustic camera, except that the two high-
frequency transducers are replaced by a light source, typically
a laser, and an optical detector, such as a photomultiplier tube
or photodiode. Mie scattering theory provides a direct means
of determining microbubble volume from the measured optical
signal.
Optical scattering measurements offer a few advantages
over purely acoustic methods, albeit at the cost of additional
system complexity. At low powers, a laser beam will produce
negligible heating or radiation force on a microbubble. Thus,
unlike a high-frequency ultrasound beam, it can be continu-
ously transmitted throughout an experiment. This means that
the laser can be used: 1) as means of determining the exact
position of a microbubble and triggering the acoustic excitation
and 2) as means of directly measuring microbubble volume
before, during, and after that excitation.
Tu et al. [36] demonstrated this technique using a modified
flow cytometer for the characterization of the commercial
contrast agent SonoVue. One limitation of their experiment,
however, was that the bubbles were confined by a rigid surface
during the measurements and there was considerable uncer-
tainty regarding the characterization of the sound field. More
recently, Rademeyer et al. [37] utilized a similar technique, but
confined the bubbles using a hydrodynamically focused flow,
thereby removing the effects of a rigid boundary and enabling
accurate characterization of the acoustic field. They were able
to record the volumetric responses of 12 000 bubbles in 30 min
including their initial and final sizes.
All of the techniques discussed in this section are limited by
the maximum signal-to-noise ratio that can be achieved in a
specific setup and hence in terms of the minimum bubble size
and/or amplitude of oscillation that can be detected. A further
limitation is the inability to distinguish between spherical
and nonspherical oscillations. This requires the use of direct
imaging methods discussed in the next section.
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IV. OPTICAL CHARACTERIZATION OF
ULTRASOUND CONTRAST AGENTS
Optical characterization methods rely on the acquisition of
nanosecond exposure optical images of the dynamic response
of microbubbles to ultrasound excitation [38], [39]. In con-
trast to the acoustic characterization techniques described in
Section III, optical approaches are able to resolve single
microbubbles, as the size of a microbubble is larger than the
wavelength of light. Optical measurements based on high-
speed imaging techniques can directly visualize the vibrations
of individual microbubbles in response to an ultrasound field,
as well as their interactions. The physical properties can be
inferred by varying the applied ultrasound parameters and
acquiring the radius versus time (R–t) response. Moreover,
various interesting phenomena (e.g., microbubble destruction
and lipid shedding) specific to the applied acoustic field can
be observed.
A. Ultrahigh Speed Imaging Facilities
To resolve the transient dynamics of microbubbles activated
by ultrasound at megahertz frequencies, the sampling rate
should exceed the central driving frequency by at least a factor
of eight to ten [38]. Therefore, a frame rate of at least several
millions of frames per second (fps) is required. In pioneer-
ing 1-D optical studies of microbubbles, streak imaging and
strobe imaging techniques were used [40], [41]. Subsequently,
2-D ultrahigh speed photography was developed that meets
both the temporal and the spatial requirements for 2-D visu-
alization of microbubble dynamics [42].
1) Streak Imaging: Streak imaging can continuously record
an event over time through a slit. For capturing microbubble
dynamics, it continuously acquires a single line through the
center of a bubble [40]. These 1-D images can be recorded
with a nanosecond or picosecond time interval between
frames. Alternatively, strobe imaging records microbubble
dynamics by composing images obtained repetitively using a
time-delayed single-shot method [41], [43]. However, this is
not a real-time imaging method, and is restricted to repeatable
events.
2) Ultrahigh Speed Photography: One approach to ultra-
high speed imaging of microbubble contrast agents is to
use a shutter-controlled camera such as the Imacon 200
(DRS Hadland, Cupertino, CA, USA). In this approach, a
beam splitter is used to divide an image over several recording
devices, achieving a maximum recording speed of 200 million
fps [44]. However, the number of maximum total recording
frames available is very limited (e.g., 16 frames for Imacon).
The Brandaris 128 ultrahigh speed imaging camera was
introduced in 2003 by Chin et al. [45] and specifically
designed with microbubble research in mind. The primary
image acquired is projected onto the rotating mirror, which is
mounted on a helium-driven turbine. The mirror can redirect
the light beam and sweep across the lens bank and refocus
the image onto 128 charge-coupled device (CCD) sensors.
This optical design was also employed for the development of
another high-speed rotating mirror system (UPMC Cam) [46],
with further improvements in the sensitivity, spatial resolution
Fig. 5. Schematic of the optical setup used with the Brandaris 128 camera
to optically record microbubble dynamics.
for bright field, and fluorescence imaging of microbubble
dynamics. The Brandaris 128 camera exceeded earlier gen-
erations of high-speed imaging cameras in its extremely high
frame rate (up to 25 × 106 fps) and relatively large number
of recording frames (128). The camera can be coupled with
various optical setups (e.g., a microscope lens) to suit the
experimental conditions.
In a typical experiment, the contrast agent microbubbles
are injected into a capillary tube or a chamber, which are
both optically and acoustically transparent, and mounted in a
water tank. The water tank is positioned below a microscope
connected to the Brandaris 128 camera, and is configured
with an ultrasound transducer pointing toward the optical
field of view. For each individual bubble, the camera is
able to record six movies of 128 frames, or 12 movies of
64 frames in a single run, which can be accomplished within
a few seconds [38]. Fig. 5 shows the setup of the Brandaris
128 camera.
B. Optical Characterization Techniques
Based on the ultrahigh speed imaging camera system,
many novel optical techniques have been developed to study
the acoustic behavior of UCA microbubbles. Typically, the
radial dynamic response is recorded at relatively low acoustic
pressures (tens of kilopascals), and the radius–time curves
extracted to further explore the physical properties of the
agent. In the same low-pressure regime, various interesting
physical phenomena have been observed, e.g., thresholding
behavior [47], “compression-only” response [48], and sur-
face mode vibrations [49]. At higher pressures (hundreds
of kilopascals), the violent vibrations of microbubbles tend
to disrupt the shell and are accompanied by shedding of
lipid shell materials [35], [50]–[54]. Similar optical studies
have also been made of other varieties of contrast agents,
e.g., nanodroplets and echogenic liposomes (ELIP) [55], [56].
1) Low Acoustic Pressure Regime: The volume pulsation of
a microbubble in response to an external oscillating pressure
field is a function of multiple factors, e.g., the pressure ampli-
tude, the frequency, and the physical nature of the bubble itself.
As above, most clinical UCA bubbles are encapsulated in
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Fig. 6. (a) Example ultra-high speed image frames for a microbubble
insonified by a single burst of 1.1 MHz at the applied pressure of 50 kPa. The
corresponding Diameter-time (DT) curve is shown in the third panel in (b).
Black dots represent the temporal location of each image frame with respect
to the DT curve. The scale bar represents 10 µm. (b) Radial excursions and
corresponding frequency spectrums of a microbubble with a diameter of 7.5
µm. The selection has been done between 0.7 and 1.5 MHz with a step
frequency of 200 kHz.
order to counter surface tension and stabilize the gas core.
The presence of this outer shell can dramatically influence the
microbubble acoustic behavior.
Theoretical modeling combined with optical measurement
techniques has been developed to investigate the bubble
dynamics at the low pressure regime, and physical properties
of the bubble shell were obtained. The first model was pro-
posed in [57], which incorporated experimentally determined
elasticity and viscosity parameters into the Rayleigh–Plesset
equation [58]. A more recent model was developed in [59],
which considers a nonlinear effective surface tension at the
bubble wall. Van der Meer et al. [60] employed a technique
to characterize the shell properties, by sweeping through the
driving frequency at a very low pressure (≤50 kPa) in a
single run of the Brandaris camera. The radius/diameter versus
time curves were extracted from the videos and analyzed
in the frequency domain, and resonance curves specific to
single microbubbles were reconstructed. By comparing the
experimental results with the simulated response for amounts
of microbubbles, the elasticity and viscosity of encapsulat-
ing shell can be derived. This so-called “microbubble spec-
troscopy” was applied in series of studies and showed a
damping effect and a shift of the resonance frequency due to
the presence of the shell [61]–[64]. Fig. 6 presents an example
of a recording in a “microbubble spectroscopy” experiment.
Fig. 6(a) shows example ultra-high speed image frames
recorded for a  microbubble insonified at 1.1 MHz under
the applied acoustic pressure of 50 kPa. The corresponding
Diameter-time (DT curve) is shown in the third panel in
Fig. 6(b), where the DT curves and corresponding frequency
spectrums under a series of frequencies are displayed.
2) High Acoustic Pressure Regime: UCA microbubbles
have also shown great potential for therapeutic use, e.g.,
thrombolysis [65], gene/drug delivery [66], and reversible
opening of the blood brain barrier (BBB) [67]. Relatively high
acoustic pressures (on the scale of several hundred kilopascals
to megapascals) and long ultrasound bursts (up to several
thousands of cycles) are typically used. In this pressure regime,
contrast agent microbubbles can undergo dramatic changes
in physical properties and vibration dynamics. Therefore,
characterizing the microbubble response optically is of high
clinical relevance.
a) Observations of microbubble destruction: Previous
optical studies have revealed the deflation of microbubbles
under relatively high acoustic pressures [51], [68]–[70], or
when exposed to prolonged burst ultrasound excitations.
Microbubble deflation has been ascribed to a few different
physical phenomena. One is the relatively slow gas convective
diffusion driven by the ultrasound exposure, which can happen
within hundreds of milliseconds up to a few minutes [50].
Another process is the inertial collapse and rapid destruction
of microbubbles into smaller bubbles or fragments, which is
then released into the surrounding medium. The latter process
can happen transiently (within a few ultrasound cycles) during
violent bubble vibrations [71]. Studies based on ultrahigh
speed imaging technique have shown changes in microbubble
dynamic responses relative to the immediate size reduction of
the microbubble [51], [70], [72].
To investigate the microbubble dynamics in response to
long ultrasound pulses, a new imaging mode on the Brandaris
128 camera has been developed to extend the total time span
of acquisitions [73]. The 128 CCD sensors were grouped
into separate segments, with the intersegment time set to be
as low as multiples of the rotation period of the turbine.
Successive imaging segments were distributed over the time
window of the ultrasound application. In a recent in vivo study,
the segmented imaging mode was utilized to visualize the
microbubble response in a chicken embryo model under a
prolonged ultrasound burst lasting for over 1 ms [74].
b) Observations of lipid shedding behavior: There has
been wide interest in gaining knowledge regarding lipid
shedding behavior under the exposure to ultrasound [35],
[50], [54], [75]. The loss of lipid shell material has been
found to be closely related to the accompanying microbubble
dissolution [51], [76]. Utilizing a high-speed imaging camera
Photron (operated at 50–100 kfps), lipid shedding dynam-
ics from fluorescently labeled microbubbles under ultrasound
excitations can be clearly visualized [52]. A conventional
high-speed camera can also be combined with the Brandaris
128 camera to monitor the lipid shedding behavior relative to
the microbubble vibration dynamics [35]. In an experiment in
which both the top view and the side view were captured, two
separate physical processes were observed: the detachment of
lipid particles from the microbubble shell and the subsequent
transport of shed materials by the convective streaming flow
field. The detachment of lipids was observed to occur within a
few ultrasound cycles above a certain pressure threshold, while
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Fig. 7. (a)–(c) Examples of lipid shell material shedding shown by high-speed
fluorescence imaging, recorded after the ultrasound application. Ultrahigh
speed images recorded by the Brandaris 128 camera indicate the vibration
dynamics and the destruction of microbubbles. A single burst of 100 cycles
at above 100 kPa [128 kPa for (a) and (c) and 170 kPa for (b)] was applied.
Scale bars represent 10 µm.
the transport trajectory was found to follow the streaming
flow field and is perpendicular to the nearby cell membrane.
Fig. 7 shows the shedding of lipid shell materials and the cor-
responding microbubble vibration dynamics and/or destruction
recorded by the Brandaris 128 camera.
3) Limitations and Future Prospects: The frame rate in
combination with the recording (exposure) time is in general a
limiting factor for high-speed imaging facilities. For example,
for the ultrahigh speed imaging camera Brandaris 128, the
total exposure time of each recording is restricted to 12 µs
at a frame rate of 10 Mfps. Although the segmented mode
was developed to counter this disadvantage, the intersegment
gap inhibits a full acquisition of the bubble dynamics during
the entire ultrasound exposure. Moreover, the optical setup
based on a high-speed imaging camera was relatively difficult
and expensive to build, comparing with other characterization
techniques such as the acoustical approach. In addition, the
low throughput of the high-speed imaging measurement is
another disadvantage. Measuring single microbubbles requires
diluting, selecting, and manipulating the bubble in a capillary
or flow channel, and two people are usually required to
perform a high-speed imaging experiment.
The optical system is limited by its numerical aperture and
the wavelength of the light. Optical sizing of UCAs with
a radius approaching the wavelength of light is difficult, as
it can produce a complex bubble image strongly influenced
by diffraction and scattering of the incident light. For exam-
ple, the optical resolution of the Brandaris 128 camera was
0.4 µm [45]. This can result in a bias of the size range of
the contrast agents selected for study, especially for smaller
contrast agent particles such as ELIP and Nanodroplets [77].
However, this limitation can be compensated for by fluore-
scence imaging, since no transmitted light is required,
and bubble-background contrast can be greatly enhan-
ced [38], [52]. Furthermore, during an optical measurement,
microbubbles will reside at the top of a capillary or a chamber.
Under the ultrasound excitation, the bubble does not just
undergo radial excursions, but also translational motion with
respect to the optical focal plane [78]. This can produce out-of-
focus errors depending on the amplitude of oscillation. When
the amplitude is kept below 1 µm, the error will be on the
order of 5%–10% [52].
V. SURFACE CHARACTERISTICS
A. Modeling and Mechanical Approaches
The microbubble coating plays a key role in determining
both its stability and acoustic response. Accurately measuring
the properties of microbubble coatings, however, presents
some significant challenges. The majority of existing theo-
retical models characterize the influence of the microbubble
coating in terms of an effective elasticity and effective viscos-
ity [57], [59], [79]. One way to determine these properties is
to utilize one of the methods described in Section III or IV to
obtain the radial response of the microbubble as a function of
time and then fit the data to the theoretical model. While it can
be shown that for two coating parameters, a unique solution
does exist, there will inevitably be considerable uncertainty in
the values obtained [80].
Alternative methods include micropipette aspiration [81]
and atomic force microscopy (AFM) [82]. In the former, a
small section of the microbubble coating is drawn into a glass
pipette under a known pressure and the resulting deformation
measured via optical microscopy. This technique, however,
only provides a measure of coating elasticity under quasi-
static conditions, and the relevance of this to microbubble
response at ultrasonic frequencies is unknown. In AFM, a
cantilever probe is either drawn across the microbubble surface
or actively vibrated against it in order to produce deformation
and hence determine elasticity. Again, however, the rate of
deformation is slow compared with that of acoustically driven
microbubble oscillations and the mode of deformation is
different (bending rather than dilation).
B. Fluorescence Microscopy
In applying all of the above techniques, it is implic-
itly assumed that the microbubble coating can be treated
as a continuous single-phase material. Several studies have
now demonstrated, however, that partitioning and domain
formation occur even in single-component microbubble coat-
ings [81], [83], [84] and that these domains govern the surface
microstructure and mechanical properties.
It is more appropriate therefore to consider the microbubble
coating as layer of adsorbed surfactant molecules whose
concentration can vary both with time (particularly if the
microbubble is oscillating) and position on the bubble surface.
The “elasticity” and “viscosity” of the coating are functions
of this variation in molecular concentration and thus will vary
with individual microbubble composition, time, temperature,
and other environmental conditions. There are a number of
models that have been developed on this basis [54], [59].
In order to characterize these surface properties in more
detail, a variety of different quantitative fluorescence imaging
techniques can be applied. In each case, a suitable fluorescent
molecule needs to be incorporated into the membrane in order
to probe a specific characteristic.
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Fig. 8. Microbubble shell viscosity for microbubbles fabricated using
sonication and microfluidics as measured via FLIM. Sample FLIM images
are shown for both types of microbubble (adapted from [85]).
1) Fluorescence Lifetime Imaging (FLIM): FLIM can be
used to investigate microbubble surface properties in combi-
nation with a specific type of fluorescent probe known as a
molecular rotor. The rate of decay of the fluorescent emissions
from the rotor is sensitive to its local environment. Thus, by
incorporating the rotor into the microbubble coating, it can be
used to map variations in molecular arrangement across the
microbubble surface, as shown in Fig. 8. Examples of molec-
ular rotors that can be used to interrogate phospholipid mem-
branes include boron-dipyrromethene C10 and C12. These
molecules preferentially locate in the hydrophobic “tail” region
of the membrane and so indicate the degree of molecular
interaction in this region. These interactions have been shown
in previous studies to correspond to the apparent viscosity of
the membrane [85].
In order to perform FLIM measurements on microbubbles,
the molecular rotor needs to be combined with the microbub-
ble coating during fabrication. This is typically done during the
preparation of the lipid film [86] that is subsequently hydrated
and processed to form bubbles. A fluorescence microscope
with an FLIM detector is required to perform the required
measurements, and the data then need to be fitted to a suitable
decay model to determine the corresponding lifetimes. The
Forster–Hoffman equation provides the relationship between
fluorescence lifetime and viscosity.
Hosny et al. [86] reported average measurements of
microbubble phospholipid coating viscosity of the same order
of magnitude as values derived from high-speed camera mea-
surements, but also showed that viscosity varied considerably
both between microbubbles and over the surface of individual
bubbles. One advantage of FLIM is that the timescales of
intramolecular rotation (the equivalent “rate of rotation” of
the rotor) correspond to those experienced by microbubbles
oscillating at ultrasonic frequencies. An important point to
Fig. 9. Targeted DPPC microbubbles (red fluorescent) bound to streptavidin-
coated surface (green fluorescent; covalently linked) (reproduced from [215]).
note, however, is while the measured “viscosity” and the
viscosity term appearing in theoretical microbubble models
will be closely related, they may not be equal and further
work is required in this area to formalize the definitions.
2) Fluorescence Recovery After Photobleaching:
Kooiman et al. [87] used an alternative technique to study
membrane viscosity. In their study, biotinylated phospholipid
bubbles were prepared and conjugated to fluorescent strepta-
vidin Oregon Green 488. High-resolution 3-D images (Fig. 9)
were obtained using a specialized confocal laser-scanning
microscope containing a matched pair of aligned opposing
100× objective lenses [88]. A high intensity laser was used
to bleach the fluorophores within a specified region on the
bubble, and further images were then acquired to measure
the rate at which fluorescence emissions recovered from this
region. This time is determined by the rate at which molecules
are able to diffuse over the microbubble surface, which is
itself proportional to membrane viscosity. This study also
reported viscosity values consistent with those obtained from
high-speed imaging although, again, the definition of viscosity
requires further attention.
3) Spectral Imaging: Fluorescent probes that locate prefer-
entially in the hydrophilic regions of surfactant membranes can
also be used, e.g., Laurdan and its derivatives. The emission
spectrum of Laurdan shifts as a function of the dipolar
water relaxation and thus the level of hydration within its
surrounding microenvironment [89], which in turn is indicative
of molecular concentration or “packing.” This is a potentially
extremely useful measure, as both “elasticity” and “viscosity”
can be directly related to it, although the specific functional
relationships for microbubble coating materials have yet to be
defined.
Fluorescent probes of this kind can be incorporated into
microbubble coatings during preparation as above, but in this
case, measurement needs to be made of the spectral content
of the fluorescent emissions rather than the lifetime. This
requires a microscope equipped with a detector array having
the required bandwidth for a given probe. Molecular packing
is defined in terms of a “generalized polarization” (GP, ranging
from −1 to 1)
GP = I440 − I490
I440 + I490 (1)
where I440 and I490 correspond to the fluorescence intensity at
440- and 490-nm emission wavelengths, respectively. A high
GP value corresponds to a small amount of water in the
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Fig. 10. Schematic of different potential loading techniques for lipid
microbubbles. All techniques are applicable to protein and polymer
microbubbles. Direct incorporation relies on the hydrophobic (or lipophilic),
hydrophilic, or amphiphilic interactions between the drug and shell. Electro-
static binding relies on charge differences between the drug or drug carrier and
shell molecules. A method not described in the text is loading the drug into an
oil layer trapped beneath the shell. Approaches relying on functionalization
of the shell and/or drug carrier include carbodiimide chemistry on exposed
carboxylic acid (–COOH) or amine (–NH2) groups, tagging with avidin
or biotin to form an avidin–biotin bond and using pyridyl disulphide or
maleimide to link to exposed sulfhydryl (–SH) groups.
vicinity of the probe and hence to a high degree of molecular
packing.
C. Electron Microscopy
Direct visualization of the microbubble surface at the
nanoscale requires the superior spatial resolution of electron
microscopy (EM). Unfortunately, the vacuum environment
inside the EM system makes it extremely challenging to
image microbubbles intact. Microbubbles have nevertheless
been successfully examined using a variety of both scanning
EM and TEM techniques.
For example, polymer-coated microbubbles have been
imaged in [90] and [91]. Vlaskou et al. [92] and
Hitchcock et al. [93] studied acoustically active liposomes by
embedding them in gelatin blocks that were then sectioned
and stained with uranyl acetate and/or lead citrate. Freeze
fracture TEM has also been employed in [81] and [83]
to study the surface of phospholipid coated microbubbles.
Owen and Stride [84] recently proposed a low-cost method for
examining microbubbles intact under TEM, using the uranyl
acetate stain itself to stabilize the bubbles. This enabled visu-
alization of nanoparticles embedded within the microbubble
coating.
VI. DRUG LOADING
A. Characterization of Microbubble Chemistry
Drug loading of microbubbles can be achieved in multiple
ways, as illustrated in Fig. 10, and accurate measurement of
the amount loaded is vital in order to determine the availability
for delivery to a target area. This section will review the
main methods for determining the drug loading capacity of
a microbubble and quantity of drug actually loaded.
B. Quantification of Loading Capacity
1) Direct Incorporation: The simplest method for loading
is direct incorporation of the drug into the shell of the
microbubble. Lipid and protein microbubbles have an
amphiphilic structure, which allows loading of amphiphilic,
hydrophilic [94], or hydrophobic drugs [95]–[97]. Albumin in
particular has excellent inherent capability as a drug carrier
[98], [100]. This method is simple to employ and drugs
are rapidly released upon ultrasonic activation, but the drug
may influence shell stability, and microbubble behavior and
release may occur in areas where microbubbles are trapped,
for example, the lungs [101], spleen [102], [103], or liver
[104], [105]. The drug loading capacity of microbubbles could
be estimated using known parameters of drug loading area,
hydrophobicity, and drug solubility; however, quantification
of the loaded drug, by the methods described later, is simpler
and more accurate.
2) Electrostatic Incorporation: Direct incorporation of
hydrophilic drugs or drug carriers onto the surface of
microbubbles can also be achieved by electrostatic interac-
tion [94], [106]–[108]. Designing a microbubble with the
opposite charge of the drug or drug carrier—which may
itself be modified to achieve the desired charge—will cre-
ate an electrostatic force that binds the two components
together.
In microbubble chemistry, hydroxyl, phosphate, and car-
boxylic acid groups will confer a negative charge. Posi-
tive charges are commonly provided by protonated nitrogen
groups, e.g., amine, trimethyl amine, etc. The presence of
these groups can be confirmed by many standard chemical
tests; however, the charge conferred is of primary interest.
Zeta potential measurements, while not specifically the charge
present at the surface of the molecule, provide a useful
means for determining the charge on a molecule. How-
ever, there are some challenges associated with measuring
microbubbles in commercial machines as discussed below.
Due to their semirigid cross-linked nature, shell remnants
of destroyed protein microbubbles should yield a relatively
good estimation of zeta potential, but this is not necessar-
ily the case with all materials. Consideration must also be
given to both the buffering solution and effect in plasma,
as the charge of a molecule will change with pH and ionic
strength. This may also be of use for site-specific release
in tumors where the high metabolic rate in tumor cells and
excretion of H+ ions result in acidification of the tumor
environment [110]–[112].
a) Zeta potential measurement: Zeta potential of particles
can be obtained through laser Doppler electrophoresis (LDE),
which measures MB electrophoretic mobility in an electric
field by light scattering and calculating its zeta potential.
However, the main limitation of this method is that the
buoyancy force acting on the bubbles significantly affects
their measurement as commercial systems typically have a
vertical. An alternative approach reported in [109] uses a
simple microfluidic device for obtaining the zeta potential of
three types of commercial microbubbles. The microbubbles
are suspended in a horizontal microchannel under an electrical
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Fig. 11. Experimental setup for measuring the zeta potential of microbubbles
as used in [109].
field and optically tracked as illustrated in Fig. 11. The velocity
of the bubbles is then used to calculate their zeta potentials.
By comparing LDE and the homemade device, a tenfold
improvement in measurement variation was achieved. It should
be noted that coating of the channel is needed to avoid MBs
sticking to the wall as well as reducing electro-osmotic flow
on the walls.
3) Conjugation of Drug Carriers: In many cases, perma-
nent attachment to a microbubble shell may be necessary.
In these instances, the drug is typically loaded into a secondary
drug carrier, i.e., polymeric nanoparticles or liposomes, and
attached to the microbubble via electrostatic or chemical
conjugation. This improves colocalization of the drug with the
microbubble at the site of activation and can help reduce sys-
temic toxicity by drug encapsulation. In addition, conjugation
of drug carriers to the shell can potentially increase the loading
capacity per microbubble in comparison with incorporation
into the shell. Kheirolomoom et al. [113] approximately
calculated up to 10 000 liposomes of 100 nm were loaded
via avidin–biotin linkages on to single microbubbles with
mean diameters of 1.7 µm. Compared with microbubbles only,
the attachment of these liposomes can give a nearly 35-fold
increase in the potential surface area alone [114].
Many conjugation techniques are available and many pro-
tocols exist for their use, in both the literature and from
commercial suppliers. Direct conjugation of a carrier to a shell
is possible via functional ligands; however, linker molecules
are typically employed to separate the drug carrier from the
shell. A popular linker is polyethylene glycol (PEG), due to its
low toxicity, low cost, the wide availability of different forms
and conjugates, and the ease of manipulation. PEG chains
with two differing functional groups—a heterobifunctional
ligand—can allow for very precise loading of desired carriers
with low interference.
For protein microbubbles, the PEG linker should be
conjugated onto the protein shell postproduction. Preproduc-
tion conjugation may interfere with functional groups required
for stable shell synthesis, although, with controlled reactions,
incomplete usage of functional groups could be attempted.
For lipid microbubbles, conjugation can be performed pre-
production to reduce the number of handling steps of frag-
ile microbubbles. Alternatively, PEG-lipid conjugates with
functional groups are already widely available and can be
incorporated directly during microbubble production. Unre-
acted PEG molecules can be quantified by refractive index
detection after separation from microbubbles by washing and
size exclusion chromatography [115]. In addition, quantifica-
tion of the relative and absolute amounts of specific lipids
incorporated into the shell could be performed using gas
chromatography (GC) [116], [117], Fourier transform infrared
(FTIR) spectroscopy [118], or high performance liquid chro-
matography (HPLC) [119], [120] on washed microbubbles.
HPLC combined with an evaporative light scattering (ELS)
detector has been used to determine the amounts of lipids in
commercial and research microbubble formulations [119], but
has yet to find widespread use in the field potentially due to the
low amounts of lipids used and complexity of establishing the
technique [121]. Alternatively, characterization of the available
functional groups on microbubbles can be attempted. A few
examples of the most common functional groups will be
covered here.
4) Avidin–Biotin: Avidin–biotin is one of the strongest
noncovalent bonds commonly available to researchers. It is
simple to use, and many PEG linkers or PEG-lipid conju-
gates with either biotin or avidin ligands are available. It
is highly tolerant to a wide range of buffering conditions
[122], [123] and is common in the preparation of novel
microbubble delivery or imaging agents [113], [124]–[126].
However, the bond is practically irreversible, requires addi-
tional washing and handling steps, and avidin is potentially
immunogenic, although recent research has shown that the
last point may not be of as great a concern as previously
thought [127]–[129].
Qualitative determination of incorporation into a microbub-
ble shell can be achieved by widely available fluorescent
biotin or avidin. Quantitatively, colorimetric and fluorimetric
tests using 2-(4′-hydroxyazobenzene) benzoic acid (HABA)
are available to rapidly determine biotin levels in a sam-
ple [130], [131]. This has been performed for biotinylated
albumin to determine the binding efficiency of the con-
jugation of biotin to albumin subsequently used to create
microbubbles [132] and on antibodies to be conjugated to
microbubbles via avidin–biotin [133]. However, considering
the low proportion of biotinylated lipids used in formulations,
typically ranging from 5% to 10% molar ratio, microbubbles
have not been directly investigated in this manner yet as even
fluorimetric HABA assays may struggle to determine biotin
quantities.
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5) Carbodiimide Chemistry: In carbodiimide chemistry,
a carboxylic acid group is reacted with 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), typically in the
presence of N-hydroxysuccinimide (NHS) or N-hydroxy-
sulfosuccinimide (sulfo-NHS) to improve yield, forming
a ligand capable of forming a covalent bond with amine
groups. Carbodiimide chemistry is popular as a protein linker
ligand, as amine and carboxylic acid groups are common in
protein residues. It is also popular for adding other functional
groups to a molecule, e.g., sulfhydryls, avidin, biotin, etc.
Typically, linkers use NHS due to its increased stability;
however, the reaction can be performed on carboxylic acid or
amine groups already present on the molecules without further
manipulation.
A lipid or protein microbubble shell with available car-
boxylic acid groups can be modified by EDC/NHS to bind
amine functionalized linkers or drug carriers [134], or vice
versa [135]. Lipid–PEG–NHS conjugates are available for
direct incorporation during lipid microbubble manufacture.
The carbon–nitrogen bond formed is “irreversible,” and this
may be a disadvantage for microbubble release. In addition,
the reaction can be challenging to perform and optimize as
reagents are very sensitive to pH, temperature, and time.
Quantifying EDC or NHS availability in the microbubble
shell can be a challenge as stability is dependent upon pH
and both will cleave over time. Measuring the concentration
of unreacted groups may be easier. EDC, and its hydrolyzed
decay products, can be detected by mass spectroscopy [136]
and colorimetric methods [137], [138]. NHS and sulfo-
NHS have strong absorbance at 260 nm under basic condi-
tions [139], and their unreacted conjugates can be isolated
and detected by fluorescence assay [140] or HPLC-UV using
a reversed phase column. Alternatively, during a reaction,
released NHS and sulfo-NHS can be quantified by HPLC-UV
using a hydrophilic interaction chromatography column [141].
Indirectly, a before and after assay of available amine,
e.g., 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) assay
[142], [143], and carboxylic acid groups, e.g., 5-bromomethyl
fluorescein assay [144], [145], can determine site usage.
Finally, an amine displaying a fluorescent compound can
be targeted to the activated EDC/NHS groups to determine
availability on the shell.
6) Sulfhydryl Linkages: On proteins, sulfhydryl groups are
less common than amine groups, increasing reaction selectivity
and potentially reducing interference of protein microbubble
formation. There are also many methods for adding sulfhydryls
to target drug carriers via other functional groups, for example,
Traut’s reagent [146] or N-succinimidyl S-acetylthioacetate
variants that target amine groups. The availability of these
sulfhydryl groups can be quantified by several meth-
ods [147]–[149], and commercial assay kits are availa-
ble [150], [151]. Several functional groups are capable of
binding to sulfhydryl groups; however, for microbubbles, the
authors could only find literature for the use of malei-
mide [124], [152]–[154] and pyridyl disulfide [155]–[157].
Maleimide reagents are more stable than EDC/NHS
and form permanent thioether linkages. The presence of
maleimide groups can be detected using commercially
available fluorimetric assay kits [158] or spectrophotometric
approaches [159]. The maleimide group remains in the com-
pound postreaction as a small linker.
Pyridyl disulfide forms a direct disulfide bond with
sulfhydryl groups with no linker length and release of the
pyridine-2-thione, which can be monitored by absorbance at
340 nm. This release can also be used to quantify the availabil-
ity of functional groups as the pyridyl disulfide bond cleaves
under reducing conditions, for example, in the presence
of dithiothreitol, glutathione, or tris(2-carboxyethyl)phosphine
hydrochloride. Although pyridine-2-thione has a relatively low
molar extinction coefficient that may hinder monitoring of
the reaction at low concentrations [160], Yoon et al. [157]
were able to utilize UV/VIS detection at 270 and 340 nm to
monitor the conjugation of pyridyl disulfide microbubbles to
thiolated liposomes. The bond formed with the drug carrier
is similarly not stable, which may allow drug release in the
reducing environment of tumors [161].
C. Drug Loading Quantification
Microbubbles have been developed beyond their original
diagnostic purpose into effective targeted drug delivery agents.
As with all drug therapies, knowledge of the dose delivered
is fundamental to ensuring a consistent therapeutic effect
without adverse events or severe toxicity. Quantification of
drug loading onto microbubbles is therefore vital, and the
following section will cover four broad drug types currently
in use with microbubbles. It should be highlighted, however,
that the characterization technique required will be entirely
dependent upon the drug, availability of equipment, cost, and
convenience. Furthermore, few drugs considered for targeted
microbubble and ultrasound delivery are novel. Literature will
likely be available describing standard methods of quantifica-
tion for the drug and should form the principle basis for any
choice in protocol.
Ideally, quantification should be carried out after loading,
either as a subtraction of unbound drug from total used or
as the amount of drug still in the sample. It should be noted
though that techniques to quantify the total loaded drug may
not represent actual release when used, some drugs may
become irreversibly bound to drug carrier or microbubble and
not be available. Loading can be measured on either intact or
destroyed microbubbles; however, the buoyant and light scat-
tering characteristics of intact microbubbles can interfere with
some measurement techniques. Negative pressure, sonication,
and heat are effective methods for microbubble destruction.
In all cases, effective washing will be required to remove
contaminants. This can be challenging with microbubbles due
to their sensitivity to pressure, shear stress, and handling.
Centrifugation is the most common method for washing
microbubbles, but will inevitably cause some concentration
loss and change in size distribution [162]. For sufficiently
stable microbubble complexes, buoyancy over time may allow
purification [163]–[165].
If the drug is difficult to detect, or difficult to separate
from the influence of the carrier or microbubble, quantification
of the drug carrier could be attempted instead. Fluorophores,
either attached to the carrier or carried with the drug, allow
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easy quantification of loading onto microbubbles by spec-
trophotometry. In addition, fluorescent drug carriers can act
as convenient markers, for example, of delivered “dose,”
delivery distances from blood vessels, distribution through-
out target tissue, off-target dose, and method of excretion.
Radiolabeled drug carriers may also fulfil this role and can
be monitored noninvasively by positron emission tomography
(PET) [166] or single photon emission computed tomography
(SPECT), although this approach has increased risk, complex-
ity, and cost. Drug carriers can also be tagged with magnetic
resonance imaging (MRI)-sensitive agents, but the equipment
required for quantification of the carrier and monitoring of
delivery may be prohibitive.
1) Cargo Types:
a) Genetic material: Genetic material is defined here as
any form of long or short chain of nucleotides, single or
double stranded, including, but not limited to, deoxyribonu-
cleic acid (DNA) [167], ribonucleic acid (RNA), messenger
RNA (mRNA), small interfering RNA (siRNA) [94], [168],
short hairpin RNA (shRNA), and potentially, some forms of
simple virus. The choice of genetic material will depend upon
application. From a loading perspective, the most important
feature shared between different types of genetic materi-
als is the presence of a negatively charged sugar-phosphate
backbone. Cationic drug carriers, such as polyethyleneimine
(PEI) [169], will load genetic material by electrostatic attrac-
tion. This loading can also protect from nuclease degradation
in vivo [170], [171]. In addition, the neutralization of the
negative can condense the genetic material to improve loading
and transmembrane passage [172].
In genetic material, the phosphate (P) groups confer a
strong negative charge. Cationic drug carriers are normally
formulated with protonated nitrogen groups (N), e.g., amine,
imizadole, trimethyl ammonium, etc. The N/P molar ratio is
commonly used to optimize electrostatic loading for genetic
material [173], [174]. As the backbone is a repeating struc-
ture, P can be calculated from the length of the genetic
material, which is either known or measurable by standard
electrophoretic techniques. For N, values for standard cationic
drug carriers, e.g., PEI, are available in the literature. Cationic
lipid components could be estimated from the initial ratios of
chemical components; however, accurate estimates can only be
achieved via analysis of the lipid constituents post production,
as mentioned earlier. Alternatively, and specifically for protein
microbubbles, there are many tests available, which can detect
protonated nitrogen groups to estimate N, for example, the
TNBS assay for primary amines [142]–[144].
Loading can be qualitatively demonstrated by measur-
ing changes in zeta potential charge as previously men-
tioned, or by the use of nucleic acid specific dyes or
stains, for example, ethidium bromide, SYBR derivatives, 4′,6-
diamidino-2-phenylindole, YOYO-1, Hoescht, and propidium
iodide [170], [175].
Many different options are available for quantitative mea-
surement of genetic material. For lipid microbubbles with-
out aromatic components, the simplest technique available is
UV spectroscopy after microbubble destruction [170], [171].
However, the correct calibration curve must be chosen, or
the genetic material purified, as different forms of genetic
material, its structure, contaminants, and buffer will affect the
absorption profile. Sensitivity of spectrophotometric methods
can be increased and contamination issues are avoided by the
use of the aforementioned dyes, although they do increase cost
and are usually hazardous. These stains may be essential for
protein microbubbles without purification as some amino acid
residues absorb in the UV range [176]. Alternatively, genetic
material can be radiolabeled to allow sensitive quantification
on intact microbubbles without issues of interference or alter-
ing loading properties [177]–[179]. However, this does further
increase cost, complexity, and potential risks.
An alternative method for both quantification and checking
for degradation of the genetic material is gel electrophoresis.
Separation of genetic material by electrophoresis can highlight
structural abnormalities by differences in migration speed
against controls [180], [181]. This method can also be
used to quantify genetic material if run against known
concentrations [182].
For all the techniques mentioned above, it should be noted
that microbubbles may leave behind charged shell remnants
after destruction, which could interfere with subsequent analy-
ses. Removal of electrostatically bound material may be
required, for instance, dissolution in 4 M guanidine hydrochlo-
ride [183]. Alternatively, standalone kits and techniques are
available to isolate genetic material from proteins. Increasing
the alkalinity of the sample could be attempted to the depro-
tonate the nitrogen groups, but this should be done at low
temperatures as a high pH will result in degradation of most
genetic material, particularly RNA [184].
(i) Chemotherapy drugs: An active area of microbubble
research is loading of established chemotherapy drugs, such
as doxorubicin [108], [168], [185]–[189], 5-fluorouracil [190],
and paclitaxel [97], [191], [192]. As chemotherapy drugs have
high systemic toxicity, the ability to direct delivery to tumor
tissue is an attractive therapy. Quantification of established
chemotherapy drugs will be well described in the literature
due to their clinical use, and the following will be general
guidance on techniques.
For some chemotherapy drugs, direct quantification may be
possible by simple fluorescence spectrophotometry, for exam-
ple, rose Bengal [193], [194], protoporphyrin IX [195], [196],
topotecan [197], [198], doxorubicin [199], and irinote-
can [200]. This also allows qualitative demonstration of load-
ing and delivery by fluorescent microscopy and histology
techniques.
For nonfluorescent drugs, alternative techniques must be
considered. Release and separation of the drug from the
microbubble or drug carrier can be followed by quantification.
Drug carriers, such as liposomes, can be disrupted by heating
to the lipid phase transition temperature, whereas polymeric
nanoparticles like PLGA can be dissolved in solvents or
broken down with sodium hydroxide.
For most drugs, literature will be available for a
variety of techniques and separation criteria. Automated
methods for separation, common in most laboratories,
are HPLC, GC, or asymmetrical flow field flow frac-
tionation (AF4). Detection is usually performed by UV
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absorbance, although many different detectors are available,
including mass spectrometry, ELS, and multilight scatter-
ing detector. For example, HPLC-UV methods have been
described for cisplatin [201], mitomycin C [202], and
5-fluorouracil [203]. In addition, certain drugs, such as
photodynamic or sonodynamic therapy drugs, generate
detectable free radicals and reactive oxygen species upon
activation [204], [205], which could be used for drug
quantification.
(ii) Proteins: Loaded proteins can include hor-
mones [126] or growth factors [206], [207]. Potentially, the
proteins could also act as a drug carrier, for instance, albumin
nanoparticles [98], [99], [115], [208]. Protein detection can be
performed by UV spectroscopy at 280 nm, but the sensitivity
is low, extinction coefficient is dependent upon sequence, and
many contaminants absorb in the same range. Instead, many
colorimetric or fluorescent assays are available for protein
quantification, e.g., the Lowry method, bicinchoninic acid
assay, and Quant-iT (see [209] for a review). Fluorescence
methods also allow qualitative assessment of loading on to
intact microbubbles. Protein samples can also be examined on
HPLC-UV machines by several methods [210], [211]. Finally,
if the protein has some intrinsic enzymatic activity, an assay
could be used to quantify both loading and integrity of the
sample.
(iii) Cells: Stem cell delivery using acoustic radi-
ation force and microbubbles is another area currently
under research [189], [212], [213]. In these cases, load-
ing is “reversed,” with one cell potentially loading multiple
microbubbles via antibodies. Optical microscopy is usually
sufficient to determine microbubble loading, although fluo-
rescent staining of the bubble with lipophilic dyes or fluo-
rophore conjugation would allow automated techniques such
as fluorescence-assisted cell sorting (FACS) to be used. FACS
would also allows sorting of cells with desired levels of
microbubble loading and a rough estimate of cell number
can be determined from absorbance at 600 nm, although this
technique should be performed without microbubbles to avoid
light scattering effects.
VII. CONCLUSION
This paper presents the means by which different research
groups have sought to characterize and compare microbubbles
for diagnostic and therapeutic applications. It is important to
note that for each of the characteristics discussed, comparison
across research labs or indeed between different investigations
within the same lab is possible only when careful consideration
of the environmental and setup conditions that may influence
microbubble behavior has been made. In addition, where
results are to be used to gain insight to behavior in vivo, careful
control of temperature, gas saturation, and preparation and
handling methods used are essential to give reliable results.
It is clear that while the case for developing a standardized
method of comparison for microbubble contrast agents is
strong, several challenges remain to support translation of new
formulations for therapy and emerging quantitative imaging
techniques from research to practice.
The characterization of polydisperse microbubble suspen-
sions by mean diameter does not capture the complexities of
size distribution or echogenic behavior. There is certainly a
case for including alongside this information details of the gas
volume distribution and description of the suspensions poly-
dispersity characteristics. There is no consensus on a reliable
and useful means of comparing microbubble acoustic behavior.
The development of the STAR method has contributed to this
discussion by providing a useful and easily understood means
of comparison, but has not seen wide adoption. This may be
in part because commercial agents, which are considered to be
well characterized, remain dominant for in vivo investigations.
It is also possible that the STAR/nSTAR value could be similar
for a contrast agent suspension that does not attenuate or
scatter effectively to one that both attenuates and scatters
effectively. However, our growing understanding of how envi-
ronmental factors influence microbubble behavior, the contin-
ued development of new, and particularly in-house fabricated
microbubbles which are particular to each research group, plus
our demands for improved insight into microbubble biophysics
to understand therapeutic applications and extend their utility
ensures that the need to accurately characterize microbubbles
will remain important.
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